Ep. 325: “Live at ISSCR 2026: Scaling and Manufacturing of PSC-Derived Therapies” Featuring Drs. Michael May and Janet Rothberg
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Ep. 325: “Live at ISSCR 2026: Scaling and Manufacturing of PSC-Derived Therapies” Featuring Drs. Michael May and Janet Rothberg
-
ナレーター：
-
著者：
In this special episode recorded live in Montréal, Canada at ISSCR 2026, Dr. Michael May, President and CEO of the Centre for Commercialization of Regenerative Medicine (CCRM), and Dr. Janet Rothberg, Senior Director of Process and Analytical Development at CCRM, explore how stem cell discoveries can be translated into commercially viable therapies through scalable manufacturing, company creation, investment, automation, and artificial intelligence. They emphasize the importance of considering manufacturing, quality control, market selection, reimbursement, and the evolving standard of care much earlier in the development process. They also share their vision for a future in which robust bioprocessing, better use of data, and improved regulatory and reimbursement models make iPSC-derived therapies more affordable and widely accessible.
Photo Reference: Courtesy of Drs. Michael May and Janet Rothberg
Subscribe to our newsletter!Never miss updates about new episodes.
Subscribe